Status:

COMPLETED

The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients

Lead Sponsor:

AstraZeneca

Conditions:

Gastroesophageal Reflux Disease

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of this study is to evaluate symptoms control and impact on daily life from patients perspective using specific GERD Impact Scale(GIS) questionnaire. The another objective is to obtain loc...

Eligibility Criteria

Inclusion

  • Patients previously diagnosed with GERD (disease duration =3 years) or newly diagnosed patients that are currently not treated with proton pump inhibitor, for whom specialist or General Practionaire (GP) have previously decided to initiate or change treatment for GERD; Patients should be treated for GERD according to current practice

Exclusion

  • Females of childbearing potential should not be pregnant or nursing

Key Trial Info

Start Date :

September 1 2010

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

November 1 2011

Estimated Enrollment :

1233 Patients enrolled

Trial Details

Trial ID

NCT01200550

Start Date

September 1 2010

End Date

November 1 2011

Last Update

April 17 2012

Active Locations (23)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (23 locations)

1

Research Site

Banja Luka, Bosnia and Herzegovina

2

Research Site

Bijeljina, Bosnia and Herzegovina

3

Research Site

Derventa, Bosnia and Herzegovina

4

Research Site

Doboj, Bosnia and Herzegovina

The Study to Describe Symptom Control and Impact on Daily Life in Gastroesophageal Reflux Disease (GERD) Patients | DecenTrialz